Immunophenotypic Profile Predictive of KIT Activating Mutations in AML1-ETO Leukemia

This publication has 33 references indexed in Scilit:

• PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
  Blood, 2006
• Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies
  Cancer Research, 2006
• STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade
  Experimental Hematology, 2005
• Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
  Journal of Clinical Oncology, 1999
• Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells
  Cancer Genetics and Cytogenetics, 1992
• t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.
  Proceedings of the National Academy of Sciences, 1991
• Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
  Cell, 1990
• Identification of a ligand for the c-kit proto-oncogene
  Cell, 1990
• Signal transduction by receptors with tyrosine kinase activity
  Published by Elsevier ,1990
• Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.
  The EMBO Journal, 1988